HK1118284A1 - Imidazo [1,2-a]pyridine compounds as vegf-r2 inhibitors - Google Patents

Imidazo [1,2-a]pyridine compounds as vegf-r2 inhibitors

Info

Publication number
HK1118284A1
HK1118284A1 HK08109446.3A HK08109446A HK1118284A1 HK 1118284 A1 HK1118284 A1 HK 1118284A1 HK 08109446 A HK08109446 A HK 08109446A HK 1118284 A1 HK1118284 A1 HK 1118284A1
Authority
HK
Hong Kong
Prior art keywords
imidazo
vegf
inhibitors
pyridine compounds
pyridine
Prior art date
Application number
HK08109446.3A
Other languages
English (en)
Inventor
David Anthony Barda
Timothy Paul Burkholder
Joshua Ryan Clayton
Yan Hao
Perry Clark Heath
James Robert Henry
John Monte Knobeloch
David Mendel
Johnathan Alexander Mclean
David Michael Remick
Mark Edward Rempala
Zhao-Qing Wang
Yvonne Yee Mai Yip
Boyu Zhong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1118284A1 publication Critical patent/HK1118284A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HK08109446.3A 2005-02-24 2008-08-25 Imidazo [1,2-a]pyridine compounds as vegf-r2 inhibitors HK1118284A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65598105P 2005-02-24 2005-02-24
PCT/US2006/006283 WO2006091671A1 (en) 2005-02-24 2006-02-23 Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors

Publications (1)

Publication Number Publication Date
HK1118284A1 true HK1118284A1 (en) 2009-02-06

Family

ID=36587138

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08109446.3A HK1118284A1 (en) 2005-02-24 2008-08-25 Imidazo [1,2-a]pyridine compounds as vegf-r2 inhibitors

Country Status (34)

Country Link
US (1) US7666879B2 (xx)
EP (1) EP1904494B1 (xx)
JP (1) JP5055136B2 (xx)
KR (1) KR100904938B1 (xx)
CN (1) CN101128461B (xx)
AR (1) AR056186A1 (xx)
AT (1) ATE490254T1 (xx)
AU (1) AU2006216710B2 (xx)
BR (1) BRPI0609047A2 (xx)
CA (1) CA2599124C (xx)
CR (1) CR9331A (xx)
CY (1) CY1111154T1 (xx)
DE (1) DE602006018615D1 (xx)
DK (1) DK1904494T3 (xx)
DO (1) DOP2006000051A (xx)
EA (1) EA011691B1 (xx)
ES (1) ES2354716T3 (xx)
HK (1) HK1118284A1 (xx)
HR (1) HRP20100677T1 (xx)
IL (1) IL184717A (xx)
MA (1) MA29433B1 (xx)
MX (1) MX2007010326A (xx)
NO (1) NO20074666L (xx)
NZ (2) NZ560402A (xx)
PE (1) PE20061098A1 (xx)
PL (1) PL1904494T3 (xx)
PT (1) PT1904494E (xx)
RS (1) RS51590B (xx)
SI (1) SI1904494T1 (xx)
TN (1) TNSN07323A1 (xx)
TW (1) TW200640924A (xx)
UA (1) UA91535C2 (xx)
WO (1) WO2006091671A1 (xx)
ZA (1) ZA200707136B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895745B2 (en) * 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
JP5442449B2 (ja) * 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
CN101669030B (zh) 2007-03-08 2016-01-13 小利兰·斯坦福大学托管委员会 线粒体醛脱氢酶2调节剂和其使用方法
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
CA2703037A1 (en) * 2007-10-17 2009-04-23 Novartis Ag Organic compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
AR090566A1 (es) * 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US9738636B2 (en) 2012-09-28 2017-08-22 Vanderbilt University Fused heterocyclic compounds as selective BMP inhibitors
KR101735975B1 (ko) * 2012-11-29 2017-05-15 에프. 호프만-라 로슈 아게 이미다조피리딘 유도체
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
AU2014365823B2 (en) 2013-12-16 2019-05-02 Abs Development 1, Inc. P2X3 and/or P2X2/3 compounds and methods
CN103772308B (zh) * 2013-12-31 2015-11-18 北京颖泰嘉和生物科技股份有限公司 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
US9988371B2 (en) 2014-06-03 2018-06-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Benzimidazole analogues and related methods
KR102485100B1 (ko) 2014-07-17 2023-01-04 선샤인 레이크 파르마 컴퍼니 리미티드 치환된 우레아 유도체 및 이의 약제학적 용도
CN104163790B (zh) * 2014-08-19 2016-02-10 贵州威顿晶磷电子材料股份有限公司 一种2-氨基-4-甲基-5溴吡啶的制备工艺
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2018526452A (ja) * 2015-09-03 2018-09-13 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ Ｄｙｒｋ１ａの小分子抑制剤およびその使用
WO2017161045A1 (en) * 2016-03-16 2017-09-21 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
MX2021007925A (es) 2018-12-31 2021-10-26 Biomea Fusion Llc Inhibidores irreversibles de la interaccion menina-mll.
EP3906029A4 (en) 2018-12-31 2022-09-21 Biomea Fusion, LLC INHIBITORS OF MENIN-MLL INTERACTION
MX2021009251A (es) * 2019-01-30 2021-09-21 Avista Pharma Solutions Inc Proceso de sintesis y nuevos compuestos intermedios.
EP3917932A4 (en) 2019-01-30 2022-09-28 Avista Pharma Solutions, Inc. CHEMICAL COMPOUNDS
US20220098204A1 (en) * 2019-02-18 2022-03-31 Shenzhen Targetrx, Inc. Substituted fused aromatic ring derivative, composition and use thereof
CN114466847A (zh) * 2019-06-25 2022-05-10 西诺普塞疗法公司 用于治疗癌症的化合物
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0888310B1 (en) 1996-03-15 2005-09-07 AstraZeneca AB Cinnoline derivatives and use as medicine
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
ES2253233T3 (es) 1999-07-09 2006-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
US6492529B1 (en) * 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
US6916814B2 (en) 2001-07-11 2005-07-12 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
CA2483084A1 (en) * 2002-05-02 2003-11-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2004052315A2 (en) * 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003298942A1 (en) * 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
CA2535416A1 (en) 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. Imidazopyridine derivatives

Also Published As

Publication number Publication date
MA29433B1 (fr) 2008-05-02
IL184717A (en) 2011-11-30
MX2007010326A (es) 2007-10-16
EP1904494A1 (en) 2008-04-02
CY1111154T1 (el) 2015-06-11
AR056186A1 (es) 2007-09-26
SI1904494T1 (sl) 2011-02-28
CN101128461B (zh) 2010-12-22
US20090227622A1 (en) 2009-09-10
EA011691B1 (ru) 2009-04-28
NO20074666L (no) 2007-11-09
BRPI0609047A2 (pt) 2010-11-16
KR100904938B1 (ko) 2009-06-29
PE20061098A1 (es) 2006-10-20
NZ584753A (en) 2011-06-30
TNSN07323A1 (en) 2008-12-31
CA2599124A1 (en) 2006-08-31
EA200701802A1 (ru) 2008-02-28
CN101128461A (zh) 2008-02-20
HRP20100677T1 (hr) 2011-01-31
KR20070099029A (ko) 2007-10-08
EP1904494B1 (en) 2010-12-01
JP5055136B2 (ja) 2012-10-24
AU2006216710A1 (en) 2006-08-31
DOP2006000051A (es) 2006-08-31
TW200640924A (en) 2006-12-01
ZA200707136B (en) 2008-11-26
ES2354716T3 (es) 2011-03-17
IL184717A0 (en) 2007-12-03
WO2006091671A1 (en) 2006-08-31
PL1904494T3 (pl) 2011-04-29
US7666879B2 (en) 2010-02-23
CR9331A (es) 2008-03-31
AU2006216710B2 (en) 2011-08-11
ATE490254T1 (de) 2010-12-15
UA91535C2 (xx) 2010-08-10
DK1904494T3 (da) 2011-02-21
JP2008531574A (ja) 2008-08-14
RS51590B (en) 2011-08-31
PT1904494E (pt) 2010-12-23
NZ560402A (en) 2010-06-25
CA2599124C (en) 2013-08-06
DE602006018615D1 (de) 2011-01-13

Similar Documents

Publication Publication Date Title
HK1118284A1 (en) Imidazo [1,2-a]pyridine compounds as vegf-r2 inhibitors
EG25765A (en) Pyrido [2,3-B] pyrazine derivatives useful as herbicidal compounds
IL204720A0 (en) Imidazo [1, 2 - a] pyridine derivatives useful as alk inhibitors
DK2137184T3 (da) Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer
BRPI0822237A2 (pt) Compostos de imidazo [1,2-a] piridina
HUS1200009I1 (hu) Pirrolo[2,3-B]piridin származékok, mint protein kináz inhibitorok
PL2124944T3 (pl) Pochodne pirazolo[3,4-b]pirydyny jako inhibitory fosfodiesterazy
ZA200802497B (en) Imidazo [1,2-A] pyridine having anti-cell-proliferation actvity
IL192236A0 (en) Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives
EP1732566A4 (en) 6-azaindole COMPOUND
ZA201204028B (en) Imidazo[1.2-a]pyridine compounds, sysnthesis thereof, and methods of using same
IL195915A0 (en) 3-amino -imidazo[1,2-a]pyridine derivatives as sglt inhibitors
IL182963A0 (en) Imidazo[1,2-a] pyridine compounds, compositions, uses and methods related thereto
ZA201004368B (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
IL190456A0 (en) Pyrazolo[4,3-d]pirimidin-5-yl)derivative used as pde5 inhibitors
EP1873154A4 (en) PYRAZOLO [1,5-A] PYRIDINE DERIVATIVE OR MEDICINALLY ACCEPTABLE SALT THEREOF
GB0714815D0 (en) Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150223